/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2025-10-29 14:06:582025-10-29 14:06:58Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting
